We're building a better ClinicalTrials.gov. Check it out and tell us what you think!
Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu

A Study of Mitoxantrone Hydrochloride Liposome Injection for Relapsing Multiple Sclerosis

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT05496894
Recruitment Status : Not yet recruiting
First Posted : August 11, 2022
Last Update Posted : August 11, 2022
Sponsor:
Information provided by (Responsible Party):
CSPC Zhongnuo Pharmaceutical (Shijiazhuang) Co., Ltd.

Brief Summary:
This is a multicenter, randomized, single-arm, open-label Phase II study to evaluate the efficacy and safety of Mitoxantrone Hydrochloride Liposome Injection with different doses in participants with Relapsing Multiple Sclerosis. Participants will be randomly enrolled into three treatment groups: Mitoxantrone Hydrochloride Liposome Injection 4 mg/m^2 group, Mitoxantrone Hydrochloride Liposome Injection 8 mg/m^2 group, and Mitoxantrone Hydrochloride Liposome Injection 12 mg/m^2 group. The primary outcome measure is the cumulative number of new Gd-enhancing lesions at the end of 48 weeks of Mitoxantrone Hydrochloride Liposome Injection treatment in brain MRI.

Condition or disease Intervention/treatment Phase
Relapsing Multiple Sclerosis Drug: Mitoxantrone Hydrochloride Liposome Injection Phase 2

Detailed Description:
Multiple sclerosis is a chronic, inflammatory, demyelinating disease of the central nervous system (CNS) and is one of the most common causes of neurological disability in young adults. It is characterised by multi-focal recurrent attacks of neurological symptoms and signs with variable recovery.This is a multicenter, randomized, single-arm, open-label Phase II study to evaluate the efficacy and safety of Mitoxantrone Hydrochloride Liposome Injection with different doses in participants with Relapsing Multiple Sclerosis. Participants will be randomly enrolled into three treatment groups: Mitoxantrone Hydrochloride Liposome Injection 4 mg/m^2 group, Mitoxantrone Hydrochloride Liposome Injection 8 mg/m^2 group, and Mitoxantrone Hydrochloride Liposome Injection 12 mg/m^2 group. The primary outcome measure is the cumulative number of new Gd-enhancing lesions at the end of 48 weeks of Mitoxantrone Hydrochloride Liposome Injection treatment in brain MRI.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 90 participants
Allocation: Randomized
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: A Phase Ⅱ Study to Evaluate the Safety and Efficacy of Mitoxantrone Hydrochloride Liposome Injection for Relapsing Multiple Sclerosis
Estimated Study Start Date : August 2022
Estimated Primary Completion Date : December 2024
Estimated Study Completion Date : August 2028

Resource links provided by the National Library of Medicine


Arm Intervention/treatment
Experimental: Mitoxantrone Hydrochloride Liposome Injection 4 mg/m^2 group
Participants will receive Mitoxantrone Hydrochloride Liposome Injection 4 mg/m^2 every 3 months (Q3M).
Drug: Mitoxantrone Hydrochloride Liposome Injection
IV, once every 3 months (Q3M)

Experimental: Mitoxantrone Hydrochloride Liposome Injection 8 mg/m^2 group
Participants will receive Mitoxantrone Hydrochloride Liposome Injection 8 mg/m^2 every 3 months (Q3M).
Drug: Mitoxantrone Hydrochloride Liposome Injection
IV, once every 3 months (Q3M)

Experimental: Mitoxantrone Hydrochloride Liposome Injection 12 mg/m^2 group
Participants will receive Mitoxantrone Hydrochloride Liposome Injection 12 mg/m^2 every 3 months (Q3M).
Drug: Mitoxantrone Hydrochloride Liposome Injection
IV, once every 3 months (Q3M)




Primary Outcome Measures :
  1. The cumulative number of new Gadolinium (Gd)-enhancing lesions at the end of 48 weeks of Mitoxantrone Hydrochloride Liposome Injection treatment in brain MRI. [ Time Frame: Week 48 ]

Secondary Outcome Measures :
  1. Annualized Relapse Rate (ARR) [ Time Frame: Week 48 ]
    ARR at Week 48 is calculated as the ratio of the sum of all participants confirmed relapse counts divided by the sum of all participants treatment duration (in years).

  2. Number of Relapses [ Time Frame: Week 48 ]
  3. Time to Onset of Confirmed Disability Progression for at least 6 Months [ Time Frame: Week 48 ]
  4. Time to Onset of Confirmed Disability Progression for at least 3 Months [ Time Frame: Week 48 ]
  5. Proportion of participants with ≥ 20% improvement from baseline in T25FW walking speed. [ Time Frame: Week 48 ]
  6. Change from baseline to Week 48 in T25FW walking speed. [ Time Frame: Week 48 ]
  7. Number of new or enlarged T2 lesions. [ Time Frame: Week 48 ]
  8. Change from baseline in brain MRI Gd-enhancing T1 lesion volume at Weeks 12、24、36、48. [ Time Frame: Week 12、24、36、48 ]
  9. Change from baseline in brain MRI T2 lesion volume at Weeks 12、24、36、48. [ Time Frame: Week 12、24、36、48 ]
  10. Number of participants with treatment-related adverse events as assessed by CTCAE v5.0 [ Time Frame: Week 56 ]
  11. Plasma concentration of Mitoxantrone Hydrochloride Liposome Injection. [ Time Frame: Week 12 ]
  12. Descriptive analysis of the rate of change in the number or proportion of B cells from baseline to different time points in different dose groups. [ Time Frame: Week 36 ]
  13. Descriptive analysis of the rate of change in the number or proportion of T cells from baseline to different time points in different dose groups. [ Time Frame: Week 36 ]
  14. Descriptive analysis of the rate of change in the number or proportion of NK cells from baseline to different time points in different dose groups. [ Time Frame: Week 36 ]


Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years to 55 Years   (Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • 18 to 55 years of age (inclusive);
  • Diagnosis of relapsing multiple sclerosis (RMS);
  • Disease duration of secondary progressive multiple sclerosis (SPMS) with superimposed relapses ≤ 5 years;
  • Expanded disability status scale (EDSS) score of 3 to 8;
  • Participants who have received disease-modifying therapy still relapse or aggravate; or participants who, in the opinion of the investigator, are suitable for treatment with Mitoxantrone Hydrochloride Liposome Injection;
  • Participants voluntarily sign informed consent, and complete the study according to the protocol.

Exclusion Criteria:

  • Pregnant or lactating female participants or participants planning to have a child during the study;
  • History of severe drug allergy, or allergy or intolerance to gadolinium, anthracyclines or liposome drugs;
  • History of vitamin B12 deficiency;
  • Participants with malignant tumor diagnosed within 5 years before the screening phase, except the skin basal cell carcinoma under effective control, and Stage I Squamous Cell Carcinoma);
  • Participants with history of interstitial lung disease or with pneumonia according to chest X-ray in the screening phase;
  • Participants with serious or active skin diseases, or clinically significant skin abnormalities in physical examination in the screening phase;
  • History of severe immunodeficiency;
  • History of drug and/or alcohol abuse, or mental disorder;
  • Participants has a progressive neurological disorder or optic neuritis other than MS; or has other disease that should be treated more preferentially than MS, or that could interfere with the study or compromise participants compliance with treatment;
  • MRI before randomization shows cervical spinal cord compression or lesions in non-MS characteristic areas of the brain, and the lesions can explain the changes in clinical symptoms and signs;
  • MS relapse in the screening phase;
  • Participated in other drug clinical studies and received investigational product within 3 months before screening or within 5 half-lives of the investigational product (whichever was longer), or participated in medical device clinical studies which is judged by the investigator to have a possible impact on the results of this study;
  • Participants who have received disease-modifying therapy or immunosuppressive agents or systemic corticosteroids within the washout period before the first dose (e.g., 4 weeks for interferon, PEGylated interferon, glatiramer acetate, dimethyl fumarate and 12 weeks for fingolimod, siponimod, intravenous immunoglobulin or plasma exchange, etc.)
  • Participants who have received anthracyclines or cardiotoxic drugs before screening;
  • Participants who previously received total body irradiation or total lymphatic irradiation, or received stem cell therapy or any type of bone marrow transplantation, or received solid organ transplantation;
  • Presence of the following clinically significant diseases: myocardial infarction, acute coronary syndrome, viral myocarditis, pulmonary embolism within 6 months; coronary revascularization within 6 months; arrhythmia requiring Class Ia or Ш antiarrhythmic drugs;
  • Laboratory tests in screening phase, such as white blood cell count, neutrophil count, platelet count, hemoglobin, creatinine clearance, etc., are abnormal with clinical significance (according to the judgment of the investigator); positive results for Hepatitis B Surface Antigen (HBsAg), Hepatitis C Antibody (HCVAb), syphilis antibody test; total bilirubin > 1.5x ULN, or alanine aminotransferase or aspartate aminotransferase > 3x ULN;
  • Participants could not complete MRI scan before randomization, such as participants with claustrophobia;
  • Participants with active or uncontrolled infection (defined as requiring systemic anti-infective therapy and the temperature ≥ 38℃ (axillary temperature) before receiving drugs and unexplainable);
  • Investigator believe that participants have other disease that are not suitable for participating in this study.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT05496894


Contacts
Layout table for location contacts
Contact: Ningning Qin, master +86-17310512621 qinningning@mail.ecspc.com

Locations
Layout table for location information
China, Beijing
Xuanwu Hospital Capital Medical University
Beijing, Beijing, China, 100000
Contact: Junwei Hao, Ph.D    +86-18810682368    Haojunwei@vip163.com   
Sponsors and Collaborators
CSPC Zhongnuo Pharmaceutical (Shijiazhuang) Co., Ltd.
Layout table for additonal information
Responsible Party: CSPC Zhongnuo Pharmaceutical (Shijiazhuang) Co., Ltd.
ClinicalTrials.gov Identifier: NCT05496894    
Other Study ID Numbers: HE071-CSP-030
First Posted: August 11, 2022    Key Record Dates
Last Update Posted: August 11, 2022
Last Verified: August 2022
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: No

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No
Additional relevant MeSH terms:
Layout table for MeSH terms
Multiple Sclerosis
Sclerosis
Pathologic Processes
Demyelinating Autoimmune Diseases, CNS
Autoimmune Diseases of the Nervous System
Nervous System Diseases
Demyelinating Diseases
Autoimmune Diseases
Immune System Diseases
Mitoxantrone
Analgesics
Sensory System Agents
Peripheral Nervous System Agents
Physiological Effects of Drugs
Antineoplastic Agents
Topoisomerase II Inhibitors
Topoisomerase Inhibitors
Enzyme Inhibitors
Molecular Mechanisms of Pharmacological Action